1.
Cureus
; 14(2): e22295, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1776615
ABSTRACT
Immune checkpoint inhibitors (ICIs) are important novel agents used in advanced non-small cell lung cancer (NSCLC) standard regimens; however, their use increases the risk of immune-related adverse effects (IRAEs). The incidence of IRAE pneumonitis is well documented in ICI use. Corticosteroids continue to be the mainstay of treatment for IRAEs. Here we report one of the first cases of using infliximab to treat durvalumab-associated pneumonitis.
2.
JAMA Netw Open
; 4(10): e2128802, 2021 10 01.
Article
in English
| MEDLINE | ID: covidwho-1460119